Introduction {#s1}
============

Primary Ovarian Insufficiency (POI) affects about 1% of women under forty years. It is often diagnosed too late, thus generating infertility and significant morbidity and mortality due to steroid-deprivation associated symptoms. Infertility is usually definitive but resumption of ovarian function occurs in \~24% of cases ([@bib27]). POI is etiologically heterogeneous (OMIM: ODG1 \# 233300. ODG2 \# 300510 ODG3 \# 614324, ODG4 \# 616185) and remains idiopathic in \~70% of the cases, but a number of genetic variants have been identified, including mutations in meiotic and DNA repair genes ([@bib27]). Consistently, several DNA repair and genomic instability disorders, such as Fanconi anemia (FA), are known to be associated with hypogonadism, ovarian failure and/or infertility. FA is a bone marrow failure syndrome accompanied by developmental defects, predisposition to leukemia, chromosome fragility and hypersensitivity to DNA interstrand crosslinks (ICL) ([@bib2]; [@bib6]). The products of the 21 genes (FANCA to FANCV) whose loss-of-function has been associated to FA are subdivided into three functional groups ([@bib2]; [@bib6]; [@bib28]). The first one, the FANCcore complex consisting of seven FA proteins (A, B, C, E, F, G, and L) and two FA-associated proteins (FAAP20 and FAAP100), is assembled in response to DNA damage and/or stalled replication forks to monoubiquitinate FANCD2 and FANCI (the second group). This monoubiquitination allows the FANCD2-FANCI heterodimer to coordinate the DNA repair/replication rescue activities of the third group of FANC proteins, which includes nucleases and proteins involved in homologous recombination. The third group includes BRCA1, BRCA2, RAD51, PALPB2 and BRIP1, whose mutations predispose to breast and ovarian cancer (BOC) ([@bib2]). However, a more recent analysis reconsidered the role of some FA-associated genes in the establishment of *bona fide* FA clinical and cellular phenotypes and excluded *FANCM* from the group of FA genes ([@bib2]). The phenotypes associated to FANCM biallelic mutations thus far are cancer predisposition, in particular early-onset breast cancer in females, and chemosensitivity. ([@bib20]; [@bib3]; [@bib5]).

Here, we have performed a whole-exome sequencing in a Finnish family with two patients presenting with non-syndromic POI and identified a homozygous truncating mutation (c.5101C\>T; p.Gln1701\*) in *FANCM*, which explains POI in these patients.

Results {#s2}
=======

The two POI patients belong to a consanguineous family ([Figure 1A](#fig1){ref-type="fig"}) without history of cancer. The parents and the 20 year old brother are reported as healthy, and the mother had regular menses at 47 years. Both patients had normal pilosity, breast and external genitalia, normal blood counts and liver balance, and had normal high-resolution karyotype and *FMR1* gene. No abnormalities in skin pigmentation and skeletal development were observed.

![Molecular analysis of the POI family.\
(**A**) Pedigree of the Finnish family with two sisters affected with POI. (**B**) Exome data visualization in IGV (Integrative Genomics Viewer) shows a high coverage of the variant position and a large number of reads in the three individuals. (**C**) Sanger sequencing confirmed the presence of the variant at a homozygous state in both affected sisters and at a heterozygous state in both parents and their brother. (**D**) Structure of the *FANCM* gene and protein, and position of the causal variant. (**E**) Western blots of FANCM in the POI family. HEK293 cell transfected with a FANCM-specific siRNA were used to validate the specificity of the anti-FANCM antibody. To transiently deplete FANCM, HEK293 cells were transfected with 20 nmol/L of small interfering RNA (siRNA) targeting FANCM, 5\'-GGC-UAC-GUC-CAG-GAG-CGC-3\' with the CaCL~2~ method. Panel present the result of a representative experiment on at least three independent analysis.](elife-30490-fig1){#fig1}

Proband had menarche at 12 years of age, with irregular cycles (20--60 days). Hormonal contraception was started at the age of 16 years for menorrhagia and stopped four years later, after which menstrual cycles became highly irregular (21--140 days). At 24 years, she had hot flushes for about one year and spaniomenorrhea. Blood hormonal assays and ultrasonographic studies of the ovaries are reported in [Table 1](#table1){ref-type="table"}. FSH level was high (41 IU/l) and AMH low. POI was diagnosed. At the age of 26, hormonal stimulation was attempted with no response. Soon after that, FSH increased to 120 IU/l and hormonal replacement was initiated.

10.7554/eLife.30490.004

###### Clinical, hormonal and ultrasonography studies of patients with *FANCM* mutation

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Case**    **Menstrual**\   **Age at evaluation**   **BMI**\       **FSH**\   **LH**\   **E2**\   **AMH**\   **T**\   **PRL**\   **TSH**\   **Ovarian surface**\   **Presence**\
              **cycles**                               (Height cm/\   IU/l       IU/l      nmol/l    ng/ml      nmol/l   mU/l       mU/l       (R/L) mm               **of follicles**\
                                                       weight Kg)                                                                                                     **at US**
  ----------- ---------------- ----------------------- -------------- ---------- --------- --------- ---------- -------- ---------- ---------- ---------------------- -------------------
  Patient-1   Secondary\       24                      22,27\         41         38        0.388                1.8      254        2.6        20 × 17 cyst/\         Yes (2)
              amenorrhea\                              (160/57)                                                                                16 × 8                 
              (24 years)                                                                                                                                              

                               26                                     120                  0.053     \<0.2               285                   26 × 11/\              Yes (1)
                                                                                                                                               18 × 8                 

                               28                                     65         51        0.120     \<0.2      0.96                                                  

  Patient-2   Spanio\          22                      24,46\         16         4         0.069                         843                                          
              menorrhea\                               (163/65)                                                                                                       
              (22 years)                                                                                                                                              

                               23                                     16                             0.6                 NA         1.7        18 × 11/\              No
                                                                                                                                               19 × 10                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI: body mass index US: ultrasonography; E2: estradiol; T: testosterone; P: progesterone; PRL: prolactin; NA: not available .

Follicular phase: 3.5-12.5 \[FSH (IU/l)\], 2.4-12.6 \[LH (IU/l)\], 0.11-0.22 \[E2 (nmol/l)\].

Ovulatory phase: 4.7-21.5 \[FSH (IU/l)\], 14-96 \[LH (IU/l)\], 0.42-1.40 \[E2 (nmol/l)\].

Luteal phase 1.7-7.7 \[FSH (IU/l)\], 1-11.4 \[LH (IU/l)\], 0.17-0.79 \[E2 (nmol/l)\].

Menopause 26-135 \[FSH (IU/l)\], 8-33 \[LH (IU/l)\], ≤ 0.05 \[E2 (nmol/l)\].

Her sister had menarche at 12 years of age, with regular menses (23 days). Hot flushes started at the age of 20 years. At 22, she consulted for hot flushes and spaniomenorrhea. She had elevated FSH (16 IU/l) and low E2 levels ([Table 1](#table1){ref-type="table"}). Incipient POI was diagnosed. As prolactin was elevated and brain MRI showed a suspected 3 mm adenoma, treatment with Parlodel was initiated. However, FSH remained elevated and AMH low ([Table 1](#table1){ref-type="table"}). At 23, hormonal stimulation was initiated with poor results. However, about 6 months later, she became spontaneously pregnant and gave birth to a healthy child.

Identification of a FANCM mutation by whole-exome sequencing and molecular studies {#s2-1}
----------------------------------------------------------------------------------

Both sisters with POI and their mother were studied by whole-exome sequencing, which generated \~45 millions of mapped read pairs per sample (91% of targeted exome at ≥10X). Exome capture, sequencing and data processing were performed as described in ([@bib11]). Variants were filtered according to the following criteria: minimum depth of 5 reads and variant quality of 20, with potential impact on transcript or protein, homozygosity in both affected sisters and heterozygosity in the mother and minor allele frequency (MAF) under 1%. The only variant fulfilling these criteria was the non-sense mutation chr14:45658326 C/T (rs147021911) in exon 20 of FANCM ([Figure 1B](#fig1){ref-type="fig"}, [Tables 2](#table2){ref-type="table"}--[3](#table3){ref-type="table"}). According to the ExAC database, its MAF is 0.0013, slightly higher in the Finnish population (0.0089), with only one homozygous individual described in the ExAC database. The variant and its segregation in the family were verified by Sanger sequencing of the exon 20 of the *FANCM* ([Figure 1C](#fig1){ref-type="fig"}). This variant leads to the p.Gln1701\* truncation at the protein level, which removes the C-terminal endonuclease and the FA associated protein 24 (FAAP24)-interaction domain ([Figure 1D](#fig1){ref-type="fig"}). FAAP24 mediates chromatin association of FANCM.

10.7554/eLife.30490.005

###### Whole Exome sequencing metrics in the Finnish family with FANCM Q1701\* variant.

  WES metrics                  mother   POI 1   POI 2
  ---------------------------- -------- ------- -------
  Gbases                       6.682    7.273   6.931
  Number of reads (millions)   44.5     48.5    46.2
  \% Alignment                 97.03    97.12   97.09
  \% Mismatch Rate R1          0.19     0.19    0.2
  \% Mismatch Rate R2          0.31     0.31    0.32
  %≥Q30 bases                  96.34    96.26   96.15
  Mean Quality Score           39.4     39.4    39.4
  Mean Depth (X)               68       74      70
  \% of bases covered at 25X   83       84      83

10.7554/eLife.30490.006

###### Whole Exome sequencing Variant filtering in the Finnish family with FANCM Q1701\* variant

  Variants called in                      Mother               POI 1   POI 2
  --------------------------------------- -------------------- ------- -------
  Total                                   40621                40343   40561
  SNPs                                    37929                37590   37859
  Indels                                  2692                 2753    2702
  **Variant filters**                     **\# of variants**           
  Shared between POI 1 and POI 2          32784                        
  in coding sequence or splice            17207                        
  in CDS, but not synonymous              8855                         
  homozygous in both POI 1 and POI 2      4053                         
  and heterozygous in Mother              512                          
  MAF \< 1% in EVS and 1000G and ExAC     5                            
  \<1% in IG exomes                       2                            
  with high potential functional impact   1                            

EBV-immortalized cells were obtained from patient 2 and the mother. Immunoblot with an anti-FANCM antibody confirmed the expression of a truncated FANCM protein of \~195 kDa in the cell line derived from the patient, whereas both the wild-type/WT (MW \~235 kDa) and the truncated proteins were present in the heterozygous mother ([Figure 1E](#fig1){ref-type="fig"}). The expression level of the truncated protein was significantly reduced compared to the WT, suggesting that the mutation destabilizes either the protein or the corresponding mRNA (i.e., non-sense mediated decay).

No variants were observed in other FANC genes. Indeed, we have exhaustively looked for the presence of variants in a list of FA genes ([Table 4](#table4){ref-type="table"}). The very good coverage of each gene (80-90X in the POI patients) excludes the possibility of having missed a variant due to a lack of coverage. The presence of heterozygous variants, both in coding regions and elsewhere (UTRs, the covered intronic sequences, etc.), in one or both POI patients, excludes the possibility of hemizygosity due to heterozygous deletions. The ratios of the number of reads of the alleles for these heterozygous variants were unbiased (i.e., close to 1) and argue against gene deletions. The detection of variants outside the coding portions of the exons also argues against the possibility of partial deletions. Exome-based CNV analysis showed that the detected CNVs were unrelated to the disease as they were either not common to the two sisters or were present in the mother. Finally, the total lack of correctly segregating variants (i.e common to both POI patients and heterozygous in the mother) in FA genes excludes the possibility of their involvement in the pathology.

10.7554/eLife.30490.007

###### Compilation of Whole-Exome-Sequencing data for the genes of the FANC pathway, excluding all the genes except FANCM as potentially harboring a causative variant.

  Gene name       Alias            Mean depth in targeted exons (1)   Nb variants in   Htz variants   Mean ratio for htz allelic   Presence of htz variants (5)   Nbr of rare variants (6)                                         
  --------------- ---------------- ---------------------------------- ---------------- -------------- ---------------------------- ------------------------------ -------------------------- ----- ----- ----- ----- ----- ------- -------
  ***FANCA***                      87.9                               94.9             90.3           29                           yes                            0.92                       no    no    yes   yes   yes   0       0
  ***FANCB***                      88.6                               93.8             89.9           2                            yes                            1.14                       no    no    no    no    no    0       0
  ***FANCC***                      64.4                               71.5             68.2           0 in this family                                                                                                             
  ***FANCD1***    ***BRCA2***      84.6                               90.5             84.5           12                           yes                            1.01                       yes   yes   no    no    no    0       0
  ***FANCD2***                     76.1                               82.1             75.0           2                            yes                            0.825                      no    no    no    yes   yes   0       0
  ***FANCE***                      89.5                               100.2            99.0           2                            yes                            1.08                       no    no    no    no    no    0       0
  ***FANCF***                      143.0                              150.2            139.7          0 in this family                                                                                                             
  ***FANCG***                      123.5                              139.8            130.2          1                            yes                            1.22                       no    no    no    no    no    0       0
  ***FANCI***                      75.7                               80.3             76.6           9                            yes                            0.89                       no    no    no    no    yes   0       0
  ***FANCJ***     ***BRIP1***      104.2                              113.0            107.7          4                            yes                            0.76                       no    no    yes   no    no    0       0
  ***FANCL***                      80.2                               88.5             80.7           3                            yes                            0.96                       no    no    no    no    no    0       0
  ***FANCM***                      86.9                               91.3             87.8           **1**                        no                             /                          no    no    no    no    no    **1**   **1**
  ***FANCN***     ***PALB2***      97.0                               106.9            101.1          0 in this family                                                                                                             
  ***FANCO***     ***RAD51C***     92.1                               103.2            94.9           1                            yes                            0.77                       no    yes   no    no    no    0       0
  ***FANCP***     ***SLX4***       107.9                              116.4            112.8          15                           yes                            0.88                       no    no    no    yes   no    0       0
  ***FANCQ***     ***ERCC4***      91.5                               98.1             90.9           2                            yes                            1.21                       no    no    yes   no    no    0       0
  ***FANCR***     ***RAD51***      75.9                               82.4             74.5           0 in this family                                                                                                             
  ***FANCS***     ***BRCA1***      87.6                               94.3             86.8           1                            yes                            0.85                       no    no    no    no    no    0       0
  ***FANCT***     ***UBE2T***      53.9                               63.2             52.6           2                            yes                            0.91                       no    no    no    no    no    0       0
  ***FANCU***     ***XRCC2***      104.3                              116.1            113.1          0 in this family                                                                                                             
  ***FANCV***     ***MAD2L2***     72.6                               85.4             74.3           0 in this family                                                                                                             
  ***FAAP100***   ***C17orf70***   69.0                               66.8             69.1           7                            yes                            0.94                       no    yes   yes   yes   no    0       0
  ***FAAP24***    ***C19orf40***   58.3                               64.6             59.2           2                            yes                            0.89                       no    no    no    no    no    0       0
  ***FAAP20***    ***C1orf86***    57.7                               62.0             59.7           3                            yes                            1.20                       yes   no    yes   yes   no    0       0
  ***FAAP16***    ***APITD1***     37.7                               44.2             40.7           4                            yes                            1.12                       no    yes   yes   no    no    0       0
  ***FAAP10***    ***STRA13***     57.3                               62.1             57.8           4                            yes                            1.18                       no    yes   no    no    yes   0       0
  ***FAN1***                       101.8                              112.9            102.6          4                            yes                            0.97                       no    no    no    yes   no    0       0
                  **mean**         **84.0**                           **91.7**         **85.9**       **110**                                                     **0.99**                                                         

\(1\) For each gene, the mean depth per exon was averaged over all exons of the gene. The high coverage for all genes excludes the possibility of not detecting a causative variant in other FANC genes.

\(2\) Total number of upstream, downstream, 5\' and 3\' UTRs, intronic, synonymous, splice site, missense, frameshift and stop variants in each gene.

\(3\) The presence of heterozygous variants in at least one of the patients excludes the possibility of hemizygosity for all genes (with the exception of the variant in FANCM that is homozygous).

\(4\) The ratio between the number of reads for each allele was averaged for all heterozygous variants in the two affected sisters. A ratio close to one for each gene indicates no bias and argues against a possible deletion for the gene.

\(5\) The presence of heterozygous variants in the various genic portions argues against the possibility of partial deletions.

\(6\) Among the 110 variants detected in the genes included in the FANC pathway, only the non-sense variant found in FANCM is homozygous in both patients, is rare (below 1% in ExAC database) and predicted as pathogenic.

FANCM is expressed in germ cells of human fetal and adult ovaries {#s2-2}
-----------------------------------------------------------------

FANCM expression was studied in germ cells of human fetal and adult ovaries. Human fetal material was obtained from the Antoine Béclère Hospital (Clamart, France) following legally-induced abortions or therapeutic termination of pregnancy. The identification of meiotic stages was performed in histological pieces that we have previously characterized ([@bib13]) and based on the chromatin features. qRT-PCR in human fetal ovaries demonstrated that FANCM mRNAs were expressed throughout ovarian development (5--32 weeks post-fertilization, wpf) ([Figure 2A](#fig2){ref-type="fig"}). Of note, expression tended to be higher than average in 14 and 17 wpf ovaries that are stages containing the highest proportion of germ cells progressing into meiotic prophase I.

![*FANCM* expression in human fetal ovaries.\
(**A**) Relative *FANCM* mRNA abundance was measured by RT-qPCR in human fetal ovaries from 5 to 32 weeks post-fertilization (wpf). (**B**) Germ cells (D2-40+) and somatic cells (D2-40-) were sorted from three ovaries ranging from 8 to 12 wpf and *FANCM* expression was measured. *ACTB* was used to normalize *FANCM* expression in all samples. Dots represent different ovaries and the mean is indicated by the line. (**C**) Immunohistochemistry of FANCM in human fetal and adult ovaries. Fetal ovaries at 8 and 22 wpf and adult ovaries were studied. FANCM positive cells appear in yellow/brown color (monoclonal FANCM CV5.1 antibody, Novus Biologicals, Abingdon, UK). Ovarian sections were counterstained with hematoxylin (blue staining). Oo, oogonia; Pa, oocyte at the pachytene stage of meiosis I, D, oocyte at the diplotene stage of meiosis I; Pr, oocyte in primordial follicle. (**D**) Co-staining in 22 wpf ovaries, for FANCM (purple) and DDX4 (brown) confirmed the germ cell identity of FANCM-positive cells (left). Successive staining for FANCM and SYCP3 in the same section (panels a and b). Negative control performed with non-immune mouse IgG (right). Scale bar: 10 μm.](elife-30490-fig2){#fig2}

Cell-sorting experiments conducted in 8--12 wpf ovaries indicated that FANCM transcripts were predominant in oogonial cells (D2-40-positive) compared to somatic cells ([Figure 2B](#fig2){ref-type="fig"}). Immunohistochemical studies in human fetal ovaries show that FANCM protein was present in the nuclei of oogonia but staining was stronger in pachytene stage oocytes (i.e., at 8 and 14 wpf respectively in [Figure 2C](#fig2){ref-type="fig"}). Of note, staining localized along the chromosomes in pachytene cells that undergo meiotic recombination. FANCM was also observed in oocytes arrested at the diplotene stage of prophase I during the last trimester of pregnancy and in adults ([Figure 2C](#fig2){ref-type="fig"}). The co-staining with Synaptonemal complex protein 3 (SYCP3) or DEAD box protein 4 (DDX4/VASA) confirmed respectively the meiotic and germinal nature of the FANCM-positive cells ([Figure 2D](#fig2){ref-type="fig"}).

The *FANCM* mutation leads to hypersensitivity to Mitomycin C and altered FANCD2 monoubiquitination in response to DNA interstrand crosslinks but not to replication inhibition {#s2-3}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Next, we monitored chromosome breakage in primary lymphocytes from the two patients and their mother. Baseline and DNA-damage induced chromosome breakage and rearrangement were blindly scored on 50 metaphases without treatment or after exposure to Mitomycin C (MMC) for 72 hr. In line with a role of FANCM in the maintenance of genome stability, the occurrence of chromosome breakages and rearrangements was higher in both POI patients than in their mother ([Figure 3A and B](#fig3){ref-type="fig"}).

![Chromosomal breakage and hypersensitivity to Mitomycin C associated to the *FANCM* 5101C \> T mutation.\
(**A**) Spontaneous and mitomycin C-induced chromosome breakage in primary lymphocytes from the mother and the two POI sisters. Data presented in table are the result of a single experiment. A minimum of 50 metaphases were scored for each sample. (**B** and **B\'**) Examples of untreated and MMC-treated metaphases from patient-2. Arrows indicate breaks and chromosome rearrangements, that is radial figures. (**C**) Western blot showing FANCD2 expression and monoubiquitination in the same lymphocytes than in A and B. Immunoblot analysis were performed using mouse monoclonal anti-FANCM antibody (CV5.1), mouse monoclonal anti-FANCD2, (Santa-Cruz Biotechnology, Dallas, Texas, USA), rabbit anti-FANCA (Abcam, Cambridge, UK), mouse anti-vinculin (Abcam). Panel present the result of a representative experiment on at least three independent analysis. (**D**) MMC-induced growth inhibition in lymphoblasts from POI patient-2 and her mother compared to the response of cells from a FANCA (HSC-72), a FANCC (HSC-536), a healthy donor (HSC-93, WT) as well as to the patient cells transduced with a WT FANCM-cDNA. The points on the lines represent the means of 3 to 7 independent experiments ± S.D. \*p\<0,05, \*\*p\<0.01, Unpaired Student\'s T test. (**E**) The recovery of the MMC-induced FANCD2-monoubiquitination following FANCM expression in cells from patient 2 is shown. (1) and (2) indicate two independent experiments. Cells were treated with MMC (500 ng/ml) and proteins extracted 24 hr later.\
10.7554/eLife.30490.010Figure 3---source data 1.File presents the original data of each growth inhibition experiment used to calculate mean and S.D. for [Figure 3D](#fig3){ref-type="fig"}.Numbers are the percentage of cell growth in treated samples compared to the untreated cells. ](elife-30490-fig3){#fig3}

We also determined the impact of the *FANCM* truncating mutation on the sensitivity to Mitomycin C and on FANCD2 monoubiquitination in response to DNA interstrand crosslinks and replication inhibition. In response to MMC, primary lymphocytes from both patients had a reduced capability to monoubiquitinate FANCD2 ([Figure 3C](#fig3){ref-type="fig"}). The reduced level of FANCD2 in lymphocytes from POI patients is likely due to a reduced proliferation of their cells in culture conditions. Next, we determined the growth inhibition response of the lymphoblasts from POI patient-2 and her mother in response to MMC ([Figure 3D](#fig3){ref-type="fig"}), as previously described ([@bib25]). The cells from the mother behaved like FANC-pathway proficient cells, while the response of the mutated cells was similar to that of FANCA- and FANCC-deficient lymphoblasts.

Finally, we assessed FANCD2 monoubiquitination in lymphoblastoid cells in response to MMC, that arrests replication by inducing DNA lesions ([Figure 4A](#fig4){ref-type="fig"}), or to two replication inhibitors, hydroxyurea (HU) and aphidicolin (APH), that block replication forks by poisoning DNA polymerases ([Figure 4B](#fig4){ref-type="fig"}). Surprisingly, whereas in response to MMC, FANCD2 monoubiquitination was clearly impaired in FANCMmut cells, those cells maintained a residual but detectable capability to monoubiquitinate FANCD2 after HU or APH treatments. Finally, consistent with a proficient DNA damage and stalled replication forks signaling in FANCM mutated cells, we failed to observe any major impairment in the MMC- phosphorylation of H2AX and CHK1 ([Figure 4A](#fig4){ref-type="fig"}) ([@bib9]).

![The *FANCM* 5101C\>T mutation leads to altered FANCD2 monoubiquitination in response to DNA damage but not to replication inhibition.\
Western blot showing FANCD2 monoubiquitination, CHK1 and H2AX phosphorylation in response to MMC (**A**), or HU or APH (**B**) in cells from patients 2 and her mother. FANCA (HSC-72) and FANCD2 (GM16756) lymphoblasts were used for comparison. Each panel presents the result of a representative experiment on at least three independent analysis. Proteins were extracted 24 hr after exposure to genotoxins.](elife-30490-fig4){#fig4}

To further validate that the identified bi-allelic mutation in *FANCM* was responsible for the MMC hypersensitivity observed in the patient\'s lymphoblasts, we transduced them with a FANCM-WT cDNA-expressing lentiviral vector (see Materials and methods). Transiently genetically complemented cells recovered a significant resistance to MMC ([Figure 3D](#fig3){ref-type="fig"}) as well as an improved monoubiquitination of FANCD2 in response to MMC ([Figure 3E](#fig3){ref-type="fig"}).

Discussion {#s3}
==========

The two patients with POI studied here belong to a consanguineous family and are thus homozygous for the FANCM mutation inherited from their parents. Our *FANCM* mRNA and protein expression studies in the developing human ovary suggest that the expression of *FANCM* starts in mitotic germ cells (first trimester of pregnancy) notably along chromosome axes and increases at the onset of meiosis (second trimester) that are maintained up to the diplotene stage in follicles. Given the known role of FANCM to sustain primordial germ cell proliferation in mouse ([@bib18]) and its conserved function during meiotic recombination ([@bib17]; [@bib8]), it is likely that both processes are sensitive to a *FANCM* mutation.

FANCM is a nuclear partner of the FANCcore complex, belonging to the FANC pathway that promotes DNA repair and safeguards replication. Indeed, FANCM is targeted to damaged DNA and/or stalled replication forks by its partners FAAP24, FANCM-interacting histone fold protein 1 (MHF1) and 2 (MHF2), where it recruits the FANCcore complex to monoubiquitinate FANCD2 and FANCI and coordinates DNA repair/replication rescue ([@bib6]; [@bib20]) allowing the faithful transmission of undamaged chromosome to the daughter cells. Consistently, the occurrence of chromosome breakages and rearrangements was higher in both POI patients than in their mother ([Figure 3A and B](#fig3){ref-type="fig"}). Our biochemical studies show that lymphocytes from both patients have a reduced capability to monoubiquitinate FANCD2 in response to MMC pointing to a defect in the activation of the FANCcore complex in FANCMmut cells. However the cells maintained a detectable capability to monoubiquitinate FANCD2 in response to HU or APH treatments.

A previous study links POI to other breast cancer genes such as BRCA1 ([@bib23]). Although recent works established a link between the heterozygous c.5101C\>T *FANCM* truncating mutation and BOC predisposition in the Finnish population ([@bib16], [@bib15]; [@bib22]), there is no history of BOC in the family investigated here. Interestingly, a few apparently healthy (i.e., without cancer) individuals homozygous for the c.5101C\>T FANCM mutation were identified in previous studies ([@bib16], [@bib15]; [@bib22]). Indeed, the authors stated, by direct observation or by looking at registered clinical data, that none of them presented FA stigmata (although no data on age, sex or clinical findings was made available). This is in line with the fact that previously identified bi-allelic inactivating *FANCM* mutations in a few FA patients co-occurred with mutations in other FANC genes, which were indeed responsible for FA ([@bib7]; [@bib26]). This has led to the recent exclusion of *FANCM* from the group of the bona fide FA genes ([@bib2]). Very recently two studies report that the phenotypes associated to FANCM biallelic mutations thus far are cancer predisposition, in particular early-onset breast cancer in females, and chemosensitivity ([@bib5]; [@bib3]). In one study ([@bib5]), two female patients out of five had premature menopause and one patient had an early reduction of the ovarian reserve according to her AMH levels.

Our results suggest that the cells that harbor biallelic c.5101C\>T *FANCM* mutations maintain a FANCM residual activity allowing them to cope with the stalling of the replication forks during their normal proliferation in vivo, probably protecting individuals from the hematopoietic and developmental abnormalities that constitute the *bona fide* features of FA. However, the repair defects associated to the c.5101C\>T truncating mutation that we describe likely leads to meiotic defects and oocyte apoptosis. Oocytes deficient for DNA repair may accumulate double-strand DNA breaks over time, resulting in reduced oocyte viability ([@bib24]). Along similar lines, in *Fancm^-/-^* female mice, the ovarian cortex is depleted of primary follicles and the number of developing follicles is reduced compared to WT ovaries. However, due to a bias against *Fancm^-/-^* females, their fertility was not thoroughly investigated ([@bib1]). Antral follicles were present, albeit in reduced number, which is consistent with the observations in our patients. Some follicles might escape the DNA repair defects and achieve maturation, as epitomized by the presence of antral follicles and corpora lutea in *Fancm*-deficient mice and by the spontaneous resumption of ovarian function with pregnancy reported in one of our patients. In conclusion, in this report, we document the first case implicating *FANCM* mutations in non-syndromic POI. Our findings clearly support a genetic link between infertility and DNA-repair/cancer genes and show the necessity to perform an enhanced genetic counseling of POI patients with a long-term follow-up.

Materials and methods {#s4}
=====================

Ethics statement {#s4-1}
----------------

The study was approved by all the institutions involved. All participants gave informed consent for the study and the study was approved by the agence de Biomedecine (reference number PFS12-002).

Study approval {#s4-2}
--------------

Written informed consent was received from participants prior to inclusion in the study and the institutions involved.

Hormonal assays {#s4-3}
---------------

FSH, LH, Prolactin, TSH: Electrochemiluminescence immunoassay ECLIA, cobas kit insert Elecsys and cobas e analyzers (2013--10, V 19), Roche Diagnostics GmbH/Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim, Germany. Equipment: cobas 8000 e 602, Roche Diagnostics. Estradiol: radioimmunological assay, Spectra kits ^125^I Coated Tube Radioimmunoassay kit insert, Orion Diagnostica, Espoo, Finland.. Equipment: Gammamaster 1270, Wallac Oy, Turku, Finland. AMH: AMH Gen II ELISA. Equipment: Beckman Coulter, Inc. 250 s. Kraemer Blvd. Brea, CA 92821 U.S.A.

Cell lines and infection with a lentiviral vector {#s4-4}
-------------------------------------------------

Blood samples were collected for hormonal and genetic studies and for the production of EBV-immortalized lymphoblastoid cell lines, which was performed at the Genopole, Evry, France, following a standard in-house protocol. EBV-immortalized cells were obtained for patient 2 and her mother. HEK293 (Research Resource Identifier/RRID:[CVCL_0045](https://scicrunch.org/resolver/CVCL_0045)) cells and FANC pathway-proficient (HSC-93 (RRID:[CVCL_G049](https://scicrunch.org/resolver/CVCL_G049))), and -deficient (HSC-72 (RRID:[CVCL_G047](https://scicrunch.org/resolver/CVCL_G047)), HSC-536 (RRID:[CVCL_G045](https://scicrunch.org/resolver/CVCL_G045)) and GM16756 (RRID:[CVCL_G041](https://scicrunch.org/resolver/CVCL_G041))) cells have been previously described ([@bib4]). HSC-72, HSC-536 and GM16756 bring bi-allelic inactivating mutations in *FANCA*, *FANCC* and *FANCD2*, respectively. Lymphoblastoid cells were cultured in RPMI 1640 medium, supplemented with 12% FCS and antibiotics. Wild-type FANCM cDNA-expressing lentiviral vectors were a gift of M. Bogliolo (Dpt of Genetics and Microbiology, Universitat Autonoma de Barcelona, Spain). Production and titration of lentiviral particles were performed as described ([@bib14]). The infection was performed on retronectin-coated plates (TaKaRa Bio, CA, USA) and efficiency was assayed by testing GFP expression using flow cytometry.

Whole-exome and Sanger sequencing {#s4-5}
---------------------------------

Library preparation, exome capture, sequencing and data processing were performed by IntegraGen SA (Evry, France) according to their in-house procedures. Data analysis was performed as described in ([@bib11]). Briefly, genomic DNA libraries were prepared from 600 ng of genomic DNA from three individuals (the mother and the two affected sisters) with NEBNext Ultra kit (New England Biolabs). Target capture, enrichment and elution were performed according to manufacturer's instructions and protocols (SureSelect Human All Exon Kits Version CRE, Agilent) without modification. Libraries were sequenced on an Illumina HiSEQ 2500 as paired-end 75 bp reads. Image analysis and base calling was performed using Illumina Real Time Analysis (RTA 1.18.64) with default parameters. The various metrics of the NGS sequencing are detailed in the [Table 2](#table2){ref-type="table"}. The sequencing data was analyzed with the Illumina pipeline (CASAVA 1.8.2) for read alignment and variant calling, and an IntegraGen in-house pipeline was used for variant annotation. Annotation of kown variants was performed according to the following databases: dbSNP144 (RRID:[SCR_002338](https://scicrunch.org/resolver/SCR_002338)), 1000 Genomes Project (release_v3.20101123) (RRID:[SCR_008801](https://scicrunch.org/resolver/SCR_008801)), Exome Variant Server (ESP6500SI-V2-SSA137) (RRID:[SCR_012761](https://scicrunch.org/resolver/SCR_012761)), HapMap3 (RRID:[SCR_002846](https://scicrunch.org/resolver/SCR_002846)), ExAC r3.0 (RRID:[SCR_004068](https://scicrunch.org/resolver/SCR_004068)), COSMIC 71 (RRID:[SCR_002260](https://scicrunch.org/resolver/SCR_002260)), ClinVar 201507 (RRID:[SCR_006169](https://scicrunch.org/resolver/SCR_006169)) and an Integragen internal database (containing 201 control exomes for SNPs and 130 control exomes for Indels). The variants were filtered using IntegraGen ERISv3 platform. The number of called variants and the effect of the various variant filters on the number of remaining candidate variants are shown in [Table 3](#table3){ref-type="table"}.

The sequence of the exon 20 of the FANCM gene was verified by PCR amplification and Sanger sequencing from the genomic DNA of the available individuals, using the primers FANCM-Forward (5'-AAAACTCGACGTGCAGTAATG-3') and FANCM**-**Reverse (5'-GAGGTTTGAAGTCTGAGACTT-3').

Collection and processing of human ovaries {#s4-6}
------------------------------------------

Human fetal material was provided by the Department of Obstetrics and Gynecology at the Antoine Béclère Hospital (Clamart, France) following legally induced abortions (first trimester) or therapeutic termination of pregnancy (second and third trimesters). The fetal age was evaluated by measuring the length of limbs and feet as previously described ([@bib10]). Adult human ovaries were provided by the Laboratory of Pathology of Gustave Roussy Institute (Villejuif, France) following prophylactic removal due to breast cancer. Adult ovaries did not present any pathological aspect, showing corpora lutea at various stages of regression compatible with at least three successive ovulatory cycles. All women provided an informed consent and this study was approved by the Biomedicine Agency (reference number PFS12-002). Tissue was either snap-frozen for RNA analysis of formalin-fixed for immunohistochemistry studies.

Expression time-course of FANCM transcripts in fetal ovaries {#s4-7}
------------------------------------------------------------

Human fetal material was obtained from the Antoine Béclère Hospital (Clamart, France) following legally-induced abortions or therapeutic termination of pregnancy. The fetal age was evaluated as previously described ([@bib10]). All women provided an informed consent and this study was approved by the Biomedicine Agency (reference number PFS12-002). After collection, fetal ovaries were stored in RNA lysis buffer (RLT) (Qiagen Courtaboeuf, France) for gene expression profiling. For some experiments human gonads were dissociated and germ and somatic cells were sorted using M2A (D240/PODOPLANIN) as previously described ([@bib21]). The M2A antigen was first reported as being present in testicular germ cells and germ cell tumors ([@bib19]). It has recently been shown that the M2A antigen is also expressed in female germ cells in the human developing ovary ([@bib13]). Sorting was performed using a BD-Influx biohazard system (BD Biosciences; San Jose, CA; USA) with the D2-40-positive cells being mostly germ cells. Total RNA from fetal ovaries and sorted cells was extracted using the RNeasy Mini Kit (Qiagen). The 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) and SYBR-green labelling were used for quantitative RT-PCR (RT-qPCR). The comparative ΔΔcycle threshold method was used to determine the relative quantities of mRNA using ACTB (ß-actin) mRNA as reference gene for normalization. Each RNA sample was analyzed in duplicate. The sequences of oligonucleotides used for amplification are:

FANCM ForwardExp (5'-GAGGAGCTTGTCCCGCTG-3'),

ReverseExp: (5'-TGACTAGTTCTCTTACAACCTGGCAATA-3');

B-ACT Forward: (5'-TGACCCAGATCATGTTTGAGA-3'),

Reverse (5'-TACGGCCAGAGGCGTACAGG-3').

In situ detection of FANCM protein by immunohistochemistry {#s4-8}
----------------------------------------------------------

Immunohistochemistry was performed on paraffin-embedded human fetal and adult ovaries as previously described ([@bib12]). Briefly, human fetal ovaries were fixed in 10% neutral formalin, dehydrated, embedded in paraffin and sectioned (5 μm) as described in by ([@bib12]). Slides were deparaffinized, rehydrated and heated to 98°C in 0.05% citraconic anhydride, pH 7.4 (Sigma-Aldrich Corp.), for 45 min and then blocked for 1 hr in 10% fetal calf serum at room temperature. After washing in phosphate-buffered saline, slides were incubated overnight with anti-FANCM antibody (CV5.1, Novus biologicals, Abingdon, UK, dilution 1/500) (RRID:[AB_2716711](https://scicrunch.org/resolver/AB_2716711)). After washing, slides were incubated with goat anti-mouse secondary antibody for 90 min at room temperature and rinsed in phosphate-buffered saline. Slides were then incubated in 3,3′-diaminobenzidene (DAB substrate kit for peroxidase; Vector Laboratories, Burlingame, CA; SK-4100), and after staining development, they were counterstained with hematoxylin and mounted in Eukitt (Sigma). Similarly, for double immunostaining anti-SYCP3 (NB300-232, Novus biological) (RRID:[AB_2087193](https://scicrunch.org/resolver/AB_2087193)) and anti-DDX4 (ab13840, Abcam) (RRID:[AB_443012](https://scicrunch.org/resolver/AB_443012)) antibodies were used and VIP (Vector laboratories) was used as a second substrate.

Chromosome breakage analysis {#s4-9}
----------------------------

Primary lymphocytes were cultured under standard conditions for karyotyping. Baseline and DNA damage induced chromosome breakage and rearrangement were scored blinded on 50 metaphases. DNA damage was induced with Mitomycin C (MMC, Sigma) added for 72 hr.

Immunoblot analysis {#s4-10}
-------------------

Immunoblots were performed as described ([@bib4]). The antibodies used were: mouse monoclonal anti-FANCM antibody (CV5.1, Novus biologicals, Abingdon, UK) (RRID:[AB_2716711](https://scicrunch.org/resolver/AB_2716711)), mouse monoclonal anti-FANCD2, (Santa-Cruz Biotechnology, Dallas, Texas, USA, SC-20022) (RRID:[AB_2278211](https://scicrunch.org/resolver/AB_2278211)), rabbit anti-FANCA (Abcam) (Bethyl Laboratories, Montgomeryn Texas, USA, Cat\# A301-980A RRID:[AB_1547945](https://scicrunch.org/resolver/AB_1547945)), mouse anti-vinculin (Abcam) (RRID:[AB_11156698](https://scicrunch.org/resolver/AB_11156698)), Rabbit anti-CHK1 antibody from Santa-Cruz Biotechnology (SC-8408) (RRID:[AB_627257](https://scicrunch.org/resolver/AB_627257)), mouse monoclonal anti-Phospho-CHK1 (Ser317) antibody from Cell Signaling Technology (\#2344) (RRID:[AB_331488](https://scicrunch.org/resolver/AB_331488)), monoclonal anti-phospho-H2AX (Ser139) antibody from Millipore (RRID:[AB_309864](https://scicrunch.org/resolver/AB_309864)). To transiently deplete FANCM, HEK293 cells (RRID:[CVCL_0045](https://scicrunch.org/resolver/CVCL_0045)) were transfected with 20 nmol/L of small interfering RNA (siRNA) targeting FANCM, 5\'-GGC-UAC-GUC-CAG-GAG-CGC-3\' with 8 μL INTERFERin (Polyplus) in Opti-MEM. The protein bands were visualized and recorded using an ImageQuant apparatus. Western blot quantifications were performed using densitometry measures and the ImageJ software.

Growth inhibition analysis {#s4-11}
--------------------------

Measurement of MMC growth inhibition was performed as previously described ([@bib25]). Measurement of Mitomycin C (MMC, Sigma) growth inhibition was performed as previously described ([@bib4]). Briefly, 5−10 × 105 cells/wells were seeded in 24-wells plate in 1 ml of complete culture medium, and left untreated or exposed to various concentration of MMC. After a growth period of 3--5 days, cells were counted in a Coulter counter. Growth percentage was calculated as follows: % Growth = 100 Xfinal number MMC-treated cells/final number untreated cells.

Web resources dbSNP144, <https://www.ncbi.nlm.nih.gov/projects/SNP/> (RRID:[SCR_002338](https://scicrunch.org/resolver/SCR_002338))

1000 Genomes Project (release_v3.20101123), <http://www.internationalgenome.org/> (RRID:[SCR_008801](https://scicrunch.org/resolver/SCR_008801))

Exome Variant Server (ESP6500SI-V2-SSA137), <http://evs.gs.washington.edu/EVS/> (RRID:[SCR_012761](https://scicrunch.org/resolver/SCR_012761))

HapMap3, <ftp://ftp.ncbi.nlm.nih.gov/hapmap/> (RRID:[SCR_002846](https://scicrunch.org/resolver/SCR_002846))

ExAC r3.0, <http://exac.broadinstitute.org/> (RRID:[SCR_004068](https://scicrunch.org/resolver/SCR_004068))

COSMIC 71, <http://cancer.sanger.ac.uk/cosmic> (RRID:[SCR_002260](https://scicrunch.org/resolver/SCR_002260))

ClinVar 201507, <https://www.ncbi.nlm.nih.gov/clinvar/> (RRID:[SCR_006169](https://scicrunch.org/resolver/SCR_006169))

Exac database: <http://exac.broadinstitute.org/> (RRID:[SCR_004068](https://scicrunch.org/resolver/SCR_004068))

OMIM: <http://omim.org/> (RRID:[SCR_006437](https://scicrunch.org/resolver/SCR_006437))
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Australia

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"A homozygous FANCM mutation underlies familial non-syndromic primary ovarian Insufficiency\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jessica Tyler as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Jordi Surralles (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

You describe two sisters with premature ovarian failure and homozygous FANCM mutations. Several previous studies have pointed to a role for FANCM and other FA genes in meiosis, and mouse models of FANCM deficiency also have ovarian failure. This led the authors to conclude that FANCM is causative in this family. Unfortunately, because the siblings are related and have consanguineous parents, the evidence for FANCM being the causative gene is not yet definitive. The reviewers discussed that while the genetic/molecular part of the study is technically well performed, the manuscript is limited in its methodology and findings. None-the-less, they all felt that the study is important given the general interest surrounding identification of new POI genes, and in individuals with homozygous FANCM deficiency.

Essential revisions:

The reviewers raise a number of concerns that must be adequately addressed before the paper can be accepted. Some of the required revisions will likely require further experimentation within the framework of the presented studies and techniques.

1\) Genetic complementation of the FANCM deficient cells must be performed, to conclusively demonstrate the role of FANCM in the cellular phenotypes observed. As an alternative (or in addition), the authors could attempt to identify and characterize additional FANCM bialelics in a POI cohort. Either one of these analyses would exclude the possibility that undetected mutations in other FA genes (deep intronic, large deletions, mutations in low coverage/non covered regions, etc...) are present. This is important when dealing with FANCM given that the first case reported by H. Joenje and co-workers turned out to also bear mutations in FANCA.

2\) Pachytene oocytes were identified as a stage of high FANCM expression. However, it is very difficult to determine meiotic stage in formalin fixed embryonic ovaries using IHC because nuclear morphology is lost. Co-staining of FANCM with meiotic markers should be performed in order to precisely determine at which stages of oogenesis FANCM is expressed. Negative (isotype) controls must also be included.

3\) The authors should reference two new studies that have identified FANCM homozygous patients with cancer predisposition (Genetics in Medicine, 2017) as well as a previous study that links primary ovarian failure to other breast cancer genes such as BRCA1: Oktay et al., 2010.

4\) A conclusion is made that the patient cells are not sensitive to HU and APH, but this is based only on an absence of FANCD2 ubiquitination. A sensitivity assay to one or both of these drugs must be included, or this point should be withdrawn.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"A homozygous *FANCM* mutation underlies a familial case of non-syndromic primary ovarian Insufficiency\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Jessica Tyler (Senior editor) and the Reviewing editor.

The manuscript has been improved but there are some minor remaining issues that need to be addressed before acceptance, as outlined below:

1\) You have not correctly cited the recent FANCM homozygotes papers. In particular, in the Introduction \"The only phenotype associated to FANCM biallelic mutations thus far is a predisposition to early-onset breast cancer\" and in the Discussion section but Bogliolo et al. describe only \*male\* patients, who develop B-LL and head and neck cancers. Both papers also highlight a chemotherapy sensitivity in FANCM homozygotes, which should be considered a \"phenotype\". A more appropriate sentence might be: \"The only phenotypes associated to FANCM biallelic mutations thus far are cancer predisposition, in particular early-onset breast cancer in females, and chemosensitivity\". In addition, it is of significant relevance that 3/5 female FANCM homozygotes in the Catucci et al. paper are characterised as having \"early onset menopause\", which is indicative of POI and thus supportive of the findings in your paper. These points need to be added to the manuscript.

2\) In Frydman, et al. paper, the antibody used seems to be expressed in oogonia and not meiotic oocytes. This means that while you have likely sorted germ cells from somatic cells, you probably do not have the population that has the highest FANCM protein expression and or the germ cells that are actually undergoing recombination (this might explain why you didn\'t see a statistically significant increase in mRNA expression in [Figure 2B](#fig2){ref-type="fig"}). You should clearly specify in what stage of \"germ cells\" you are measuring expression.

3\) In subsection "FANCM is expressed in germ cells of human fetal and adult ovaries" you refer to \"...an increase in ovaries containing germ cells progressing into meiotic prophase 1\". The n=2 at 14-17wks prevents statistical analysis, so it is not appropriate to refer to an increase in this instance.

10.7554/eLife.30490.015

Author response

> Essential revisions:
>
> 1\) Genetic complementation of the FANCM deficient cells must be performed, to conclusively demonstrate the role of FANCM in the cellular phenotypes observed. As an alternative (or in addition), the authors could attempt to identify and characterize additional FANCM bialelics in a POI cohort. Either one of these analyses would exclude the possibility that undetected mutations in other FA genes (deep intronic, large deletions, mutations in low coverage/non covered regions, etc...) are present. This is important when dealing with FANCM given that the first case reported by H. Joenje and co-workers turned out to also bear mutations in FANCA.

We have exhaustively looked for the presence of variants in a list of FA genes (new [Table 4](#table4){ref-type="table"}). The very good coverage of each gene (80-90X in the POI patients) excludes the possibility of having missed a variant due to a lack of coverage. The presence of heterozygous variants, both in coding regions and elsewhere (UTRs, the covered intronic sequences, etc.), in one or both POI patients, excludes the possibility of hemizygosity due to heterozygous deletions. The ratios of the number of reads of the alleles for these heterozygous variants were unbiased (i.e., close to 1) and argue against gene deletions. The detection of variants outside the coding portions of the exons also argues against the possibility of partial deletions. Exome-based CNV analysis showed that the detected CNVs were unrelated to the disease as they were either not common to the two sisters or were present in the mother. Finally, the total lack of correctly segregating variants (i.e common to both POI patients and heterozygous in the mother) in FA genes excludes the possibility of their involvement in the pathology. These analyses show that the cellular phenotypes observed in the cells of the patients are not due to mutations in FA genes other than FANCM. These results have been added to subsection "Identification of a FANCM mutation by whole-exome sequencing and molecular studies." and in [Table 4](#table4){ref-type="table"}.

Moreover, we performed a genetic complementation of the FANCM deficient cells of patient 2 wich significantly increased their resistance to MMC exposure (with p values \<0.05 or \<0.01 according to the concentration of MMC used) and restored FANCD2-monoUbiquitination. The results are shown in subsection "The *FANCM* mutation leads to hypersensitivity to Mitomycin C and altered FANCD2 monoubiquitination in response to DNA interstrand crosslinks but not to replication inhibition" and in [figures 3D](#fig3){ref-type="fig"} and E. See also subsection "Cell lines and infection with a lentiviral vector" and subsection "Whole-exome and Sanger sequencing".

> 2\) Pachytene oocytes were identified as a stage of high FANCM expression. However, it is very difficult to determine meiotic stage in formalin fixed embryonic ovaries using IHC because nuclear morphology is lost. Co-staining of FANCM with meiotic markers should be performed in order to precisely determine at which stages of oogenesis FANCM is expressed. Negative (isotype) controls must also be included.

The identification of meiotic stages was performed in histological pieces that have we previously characterized (Frydman, 2017) and based on the chromatin features. Unfortunately, due to incompatibility of the antibodies in double immunostaining experiments it was not possible to obtain satisfying results with the SYCP3/FANCM co-staining after trying several IF protocols. We thus performed immunohistochemistry using VIP, a washable substrate, to stain first FANCM and subsequently SYCP3. We now also provide evidence that FANCM is present in DDX4+ cells (germ cells). Additionally, we provide a negative control. See subsection "In situ detection of FANCM protein by immunohistochemistry", subsection "FANCM is expressed in germ cells of human fetal and adult ovaries**"** and new [Figure 2D](#fig2){ref-type="fig"}.

> 3\) The authors should reference two new studies that have identified FANCM homozygous patients with cancer predisposition (Genetics in Medicine, 2017) as well as a previous study that links primary ovarian failure to other breast cancer genes such as BRCA1: Oktay et al., 2010.

These references have been added to the Introduction, the Discussion section and to the Reference list.

> 4\) A conclusion is made that the patient cells are not sensitive to HU and APH, but this is based only on an absence of FANCD2 ubiquitination. A sensitivity assay to one or both of these drugs must be included, or this point should be withdrawn.

Accordingly, to the suggestion, the point has been withdrawn.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> 1\) You have not correctly cited the recent FANCM homozygotes papers. In particular, in the Introduction \"The only phenotype associated to FANCM biallelic mutations thus far is a predisposition to early-onset breast cancer\" and in the Discussion section but Bogliolo et al. describe only \*male\* patients, who develop B-LL and head and neck cancers. Both papers also highlight a chemotherapy sensitivity in FANCM homozygotes, which should be considered a \"phenotype\". A more appropriate sentence might be: \"The only phenotypes associated to FANCM biallelic mutations thus far are cancer predisposition, in particular early-onset breast cancer in females, and chemosensitivity\". In addition, it is of significant relevance that 3/5 female FANCM homozygotes in the Catucci et al. paper are characterised as having \"early onset menopause\", which is indicative of POI and thus supportive of the findings in your paper. These points need to be added to the manuscript.

According to the suggestion of the reviewer we have changed the sentence in the Introduction and the Discussion section: "The phenotypes associated to FANCM biallelic mutations thus far are cancer predisposition, in particular early-onset breast cancer in females, and chemosensitivity\", and also in the Discussion section: "In one study (Catucci et al., 2017) two female patients out of five had premature menopause and one patient had an early reduction of the ovarian reserve according to her AMH levels".

> 2\) In Frydman, et al. paper, the antibody used seems to be expressed in oogonia and not meiotic oocytes. This means that while you have likely sorted germ cells from somatic cells, you probably do not have the population that has the highest FANCM protein expression and or the germ cells that are actually undergoing recombination (this might explain why you didn\'t see a statistically significant increase in mRNA expression in [Figure 2B](#fig2){ref-type="fig"}). You should clearly specify in what stage of \"germ cells\" you are measuring expression.

This is correct; M2A or D2-40 immunolabelling is strongly present in oogonia and sharply decreases from meiotic entry onwards. Our unpublished data indicate the expression of meiotic genes in some D2-40-positive cells. Nonetheless, it is likely that the majority of sorted cells are oogonia and not cells at pachytene stage, we thus changed the text in subsection "FANCM is expressed in germ cells of human fetal and adult ovaries" to specify this: "Cell-sorting experiments conducted in 8-12 wpf ovaries indicated that FANCM transcripts were predominant in oogonial cells (D2-40-positive) compared to somatic cells ([Figure 2B](#fig2){ref-type="fig"})."

> 3\) In subsection "FANCM is expressed in germ cells of human fetal and adult ovaries" you refer to \"...an increase in ovaries containing germ cells progressing into meiotic prophase 1\". The n=2 at 14-17wks prevents statistical analysis, so it is not appropriate to refer to an increase in this instance.

Text has been changed accordingly in subsection "FANCM is expressed in germ cells of human fetal and adult ovaries": "qRT-PCR in human fetal ovaries demonstrated that FANCM mRNAs were expressed throughout ovarian development (5-32 weeks post-fertilization, wpf) ([Figure 2A](#fig2){ref-type="fig"}). Of note, expression tended to be higher than average in 14 and 17 wpf ovaries that are stages containing the highest proportion of germ cells progressing into meiotic prophase I."

[^1]: These authors contributed equally to this work.

[^2]: These authors also contributed equally to this work.
